Navigation Links
Targeted Therapy Shows Promise Against Deadly Brain Cancer
Date:6/5/2010

Small trial found compound slowed drug-resistant medulloblastoma in children

SATURDAY, June 5 (HealthDay News) -- A preliminary study has found that a targeted treatment for medulloblastoma -- the most common malignant brain cancer in children -- may one day be able to treat drug-resistant forms of the disease.

"Less than 5 percent of patients currently survive medulloblastoma," said Dr. Amar Gajjar, lead author of the study, which was presented Saturday at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. "Most patients usually die 12 to 18 months after the tumor comes back."

Although this study was designed primarily to assess side effects, if the drug moves through the pharmaceutical pipeline, it would be the first targeted drug aimed at a signaling pathway. Chemotherapy is the main treatment now.

The drug, known as GDC-0449, interrupts the "sonic hedgehog" pathway, which has been implicated in a number of other cancers; it is involved in 20 percent of cases of children with medulloblastoma.

The drug has already been shown to have some effectiveness in adults with medulloblastoma that has recurred, as well as with basal cell carcinoma, a type of skin cancer.

Thirteen children with recurrent or drug-resistant brain tumors took GDC-0449 once a day for 28 days at one of two doses. The median age of the participants was about 12.

Twelve of the participants stayed the course without major side effects. One child was able to continue taking the drug for a full year without the cancer progressing.

"This demonstrates that we have taken a tumor, found a molecular subtype, found a drug which works, showed that it's safe in children and that we can have them benefit by treating these tumors using this molecular targeted therapy," said Gajjar, who is director of neuro-oncology in the department of oncology at St. Jude Children's Research Hospital in Memphis.

The research group will be moving on to a phase 2 trial. A phase 2 trial in adults is already ongoing, Gajjar said.

"Preliminary analysis has shown benefits to these [adult] patients," he noted.

Because this was such an early trial, "we don't yet know what impact this drug is going to have on survival," said Dr. Lynn Schuchter, moderator of a news conference involving the trial and a professor of medicine at the Abramson Cancer Center at the University of Pennsylvania. "We don't have a lot of data on follow-up, but this is really an amazing proof-of-principle idea and this pathway looks to be relevant in many cancers."

Schuchter reported ties to drug maker Pfizer Inc., while Gajjar reported no such ties.

More information

Children's Hospital Boston has more on medulloblastoma.



SOURCES: June 5, 2010, news conference with Lynn Schuchter, M.D., professor, medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, and Amar Gajjar, M.D., director, neuro-oncology division, department of oncology, St. Jude Children's Research Hospital, Memphis, Tenn.; June 5, 2010, American Society of Clinical Oncology annual meeting, Chicago


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Targeted Radiation for Early Breast Cancer a Good Option: Study
2. Blocking DNA repair protein could lead to targeted, safer cancer therapy
3. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
4. Women Smokers Targeted on World No Tobacco Day
5. Drug in new class of targeted therapies shows early promise against blood-related cancers
6. Site Steering Launches Keyword Targeted Small Business Internet Video Advertising Program That Achieves First Page Search Results Within Days
7. Gene-Targeted Therapy Might Help Prevent Paralysis
8. New targeted therapy effective in treating advanced prostate cancer
9. Kaiser Permanente Southern California to Offer FitOrbit Online Personal Training to Targeted Patients
10. Targeted agent blocked growth of deadly brain cancer in preclinical studies
11. Survival in metastatic breast cancer patients is improving: targeted therapies have contributed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... For over twenty-four years, Doctors on Liens has published a directory ... high quality medical care. When the company started in 1997, the directory was a ... day and the now ten-page directory features a vast array of medical specialists ...
(Date:12/2/2016)... ... , ... Advanced Inc., a leading provider of travel therapy and travel nursing ... as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as ... operational leadership experience to Advanced Inc. He began his career in finance at Ernst ...
(Date:12/2/2016)... ... ... Center for Autism and Related Disorders (CARD) Portland today announced plans to ... and other developmental disabilities. The group, which is being launched with the help of ... to share stories and advice, seek help, and continue their education on how to ...
(Date:12/2/2016)... ... ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover of the print ... to practice medicine at an early age by his father, who was also a ... prescribing medicine,” he states. “It is about building relationships with people; relationships that are ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet’s newest campaign, “Digestive Heath,” hits ... proof that attitude and determination can combine into the most remarkable achievements. Over ... holidays. This campaign will offer patients a new-found hope, by seizing the opportunity ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 According to a ... by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical ... Nephrology, Infectious Diseases) - Forecast to 2021" published ... USD 60.22 Billion in 2016. This market is ... during the forecast period (2016-2021) to reach USD ...
(Date:12/2/2016)... 2, 2016  The Addiction Treatment Advisory Group ... Managed Care Pharmacy (AMCP), has released detailed findings ... the opioid addiction crisis, including through improved access ... ATAG,s newly released paper, "The Role of ... addresses many issues around gaps and barriers to ...
(Date:12/2/2016)... 2016 Boston Scientific Corporation (NYSE: ... certain manufacturing assets and capabilities of the Neovasc, Inc., ... tissue business, as well as a 15% equity stake ... cash. The Neovasc advanced biological tissue business makes elements ... Lotus™ Valve System. * Upon completion of the ...
Breaking Medicine Technology: